Welcome to our dedicated page for Esperion Therapeutics news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a leading pharmaceutical company specializing in the development and commercialization of innovative, first-in-class, oral therapies aimed at lowering low-density lipoprotein cholesterol (LDL-C). The company's flagship product, ETC-1002, is a potent inhibitor of ATP citrate lyase, an enzyme integral to the cholesterol biosynthesis pathway. This pathway also includes HMG-CoA reductase, the enzyme targeted by statins.
Esperion has made significant progress with ETC-1002, completing Phase 1 and Phase 2 clinical trials, and is set to initiate Phase 3 trials. The company's product lineup includes NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to tackle elevated LDL-C levels. These drugs have recently received expanded FDA approval for cardiovascular risk reduction and are indicated for both primary and secondary prevention patients.
In recent news, Esperion announced that both NEXLETOL and NEXLIZET have received broad new label expansions. These labels now cover cardiovascular risk reduction and expanded LDL-C lowering, either alone or in combination with statins. This approval allows over 70 million patients to access these life-saving drugs, positioning them as the non-statin drugs of choice for cardiovascular risk management.
Esperion is also ramping up its marketing and promotional efforts, enhancing patient support programs, and working with payers to improve patient access. The company is committed to breaking barriers in cardiovascular care and continues to focus on underserved populations, including women and Hispanic/Latinx patients, as demonstrated by their recent CLEAR Outcomes trial.
The company's forward-looking strategy includes ongoing clinical development, financial management, and expansion into new markets. Esperion's dedication to transforming cardiovascular care is evident in its robust pipeline and strategic initiatives aimed at addressing critical unmet medical needs.
Esperion (NASDAQ: ESPR) announced on August 7, 2024, the granting of 66,800 restricted stock units (RSUs) to 18 new employees under its 2017 Inducement Equity Incentive Plan. This plan is exclusively used for equity awards to individuals who were not previously employees or non-employee directors of Esperion, as an inducement for employment.
The RSUs will vest over four years, with 25% vesting on the one-year anniversary of the recipient's vesting commencement date, and the remaining 75% vesting in twelve equal quarterly installments thereafter. Vesting is subject to continued employment with Esperion. The RSUs are governed by the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan and the RSU agreement covering the grant.
Esperion (NASDAQ: ESPR) has announced it will report its second quarter 2024 financial results on Monday, August 12, 2024, before the market opens. Following the release, the company will host a webcast at 8:00 a.m. ET to discuss the financial results and provide business updates. Investors can pre-register for the conference call to obtain dial-in information, and a live audio webcast will be accessible on Esperion's website. The webcast replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is focused on discovering, developing, and commercializing innovative medicines for patients with or at risk for cardiovascular and cardiometabolic diseases. The company aims to help patients with high cholesterol reach their LDL-cholesterol reduction goals.
Esperion (NASDAQ: ESPR) has announced its participation in the upcoming BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion is a company dedicated to discovering, developing, and commercializing innovative medicines for patients with or at risk for cardiovascular and cardiometabolic diseases.
The company focuses on improving outcomes for patients with high cholesterol by breaking through barriers that prevent patients from reaching their goals. Esperion's approach aligns with healthcare providers' trend towards reducing LDL-cholesterol levels as low as possible, as soon as possible.
For more information about Esperion and its work, interested parties can visit esperion.com and esperionscience.com, or follow the company on X (formerly Twitter) at twitter.com/EsperionInc.
Esperion (NASDAQ: ESPR) has launched a new digital marketing campaign called 'Lipid Lurkers' to educate patients about the risks of uncontrolled LDL cholesterol. The campaign uses animated characters to visually represent the unseen risk lurking in patients' artery walls. This initiative follows the recent FDA-approved label expansion for NEXLETOL and NEXLIZET, allowing Esperion to target over 70 million Americans with high LDL-C.
The digital-first strategy aims to reach adults diagnosed with high LDL-C who cannot take statins or optimize their statin therapy. Initial results show 190,000 clicks for more information in May 2024. The campaign emphasizes patient empowerment to 'Take Control of Their Lipid Lurkers' and is designed to increase awareness among the target audience through various digital channels.
Esperion (Nasdaq: ESPR) announced a Royalty Purchase Agreement with OMERS Life Sciences, securing $304.7 million in cash for its European royalty rights on bempedoic acid products. OMERS will receive tiered royalties until it recoups 1.7 times its investment, after which royalties revert to Esperion. Additionally, Esperion retains rights to potential sales-based milestones up to $300 million. The funds were used to pay off and terminate an existing revenue interest facility with Oberland Capital. This strategic move aims to enhance Esperion's financial flexibility and unencumber its balance sheet, positioning the company to better focus on U.S. commercialization efforts.
Esperion (NASDAQ: ESPR) announced its participation in upcoming June investor conferences. The company will present at the Jefferies Global Healthcare Conference in New York on June 5, 2024, at 4:30 p.m. ET, and the Goldman Sachs Healthcare Conference in Miami Beach on June 12, 2024, at 8:40 a.m. ET. Both events will be webcast live, with replays available on the Esperion website for 90 days. Esperion focuses on developing and commercializing innovative treatments for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol levels. The company aims to address the unmet health needs of millions of patients.
The European Commission has approved label updates for NILEMDO (bempedoic acid) and NUSTENDI (bempedoic acid/ezetimibe) to treat hypercholesterolemia and reduce cardiovascular risk. This approval is based on the positive results from the CLEAR Outcomes trial, making these the first and only LDL-C lowering treatments indicated for both primary and secondary prevention of cardiovascular events.
NILEMDO can lower cholesterol by up to 28% when added to statin therapy, while NUSTENDI can reduce LDL-C by 38% in high-risk patients. The Phase 3 CLEAR Outcomes trial involved 13,970 patients and showed a 13% reduction in major adverse cardiovascular events.
Despite existing treatments, up to 80% of patients do not achieve guideline-recommended LDL-C levels, highlighting the need for new options like NILEMDO and NUSTENDI. The approval aims to provide healthcare professionals with better tools to manage cardiovascular risk and reassure patients of effective treatment options.
Esperion (ESPR) and Otsuka Pharmaceutical announced that their Phase 3 trial in Japan for bempedoic acid, a treatment for hypercholesterolemia, met its primary endpoint.
The study showed a 25.25% reduction in LDL cholesterol in the bempedoic acid group compared to a 3.46% reduction in the placebo group, achieving statistical significance (p<0.01).
No serious adverse events were reported, aligning with previous trials' safety and tolerability data.
Otsuka plans to submit a New Drug Application (NDA) in Japan in late 2024 based on these results.
Bempedoic acid is already marketed in the US and Europe for reducing cardiovascular risk and LDL cholesterol levels.
Esperion (NASDAQ: ESPR) has announced that the U.S. Patent and Trademark Office (USPTO) granted a five-year Patent Term Extension (PTE) for bempedoic acid, the key ingredient in NEXLETOL® and NEXLIZET® tablets. This extension extends U.S. Patent No. 7,335,799 through December 3, 2030. Bempedoic acid is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who cannot take recommended statin therapy. It is also used to lower LDL-C in adults with primary hyperlipidemia. The PTE will be included in the FDA's Orange Book, enhancing the market exclusivity of the drug. Important safety information includes the risk of hyperuricemia and tendon rupture, among other adverse reactions.
Esperion granted 62,300 RSUs to 16 new employees under the 2017 Inducement Equity Incentive Plan. The RSUs will vest over time based on employment. Esperion focuses on developing medicines for cardiovascular diseases, striving to improve patient outcomes. For more info, visit esperion.com.
FAQ
What is the current stock price of Esperion Therapeutics (ESPR)?
What is the market cap of Esperion Therapeutics (ESPR)?
What is Esperion Therapeutics, Inc.?
What products does Esperion offer?
What recent achievements has Esperion made?
What is ETC-1002?
What is the significance of the CLEAR Outcomes trial?
Who can benefit from Esperion's medications?
What partnerships does Esperion have?
What are the common side effects of NEXLETOL and NEXLIZET?
How does Esperion support its patients?
What are Esperion's future plans?
